March 13, 2025
| This week’s gene therapy news and insights for biopharma leaders
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.
|
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell by double digits.
|
The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.
|
Discover how ENFINIA™ Linear DNA and Daciel-Arbor's myTXTL cell-free expression system rapidly characterize CRISPR-Cas systems and eliminate traditional cloning.
|
Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.
|
News roundup
The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio, Bayer’s gene therapy subsidiary, advanced an experimental treatment for limb-girdle muscular dystrophy.
|
What We're Reading
Boston Business Journal
|
The New York Times
|
Pink Sheet
|
MIT Technology Review
|
Upcoming Event
|